MediSapiens, GSK, MSKCC and University of British Columbia Publish a Joint Study on NRG1-rearranged Cancers

MediSapiens publishes a study “Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers” with GSK, MSKCC and University of British Columbia.

Scientists from GSK, Memorial Sloan Kettering Cancer Center, University of British Columbia and MediSapiens jointly published a study titled “Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers” in Cancer Discovery (OnlineFirst April 2, 2018 doi: 10.1158/2159-8290.CD-17-1004). From MediSapiens, Henrik Edgren, CSO and Anja Ruusulehto, Senior Bioinformatician contributed to this study. We are happy to have been involved in this interesting research project and excited to share the results of our joint paper.


A key finding of the study was that for NRG1-rearranged cancers, ERBB3 inhibition is highlighted as a novel treatment paradigm. Further key findings included that for the treatment of these tumors, inhibition of ERBB3 may preliminarily be more effective than inhibition of ERBB2. Based on the analysis of 8,984 tumors in The Cancer Genome Atlas and 17,485 tumors in MSK-IMPACT datasets, NRG1 rearrangements were identified in various different types of tumors, including breast, head and neck, renal, lung, ovarian, pancreatic, prostate, and endometrial cancers, and this finding supports a basket trial approach in future drug development.


MediSapiens actively participates in multiple research projects and for this study, our team contributed identification of NRG1 rearrangements across close to 9000 tumors in The Cancer Genome Atlas dataset. Our ambition is to help people live healthier lives and by participating in research projects, we are able to contribute our expertise to support novel discoveries and to promote better health.


Full citation: Drilon A, Somwar R, Mangatt BP, Edgren H, Desmeules P, Ruusulehto A, Smith RS, Delasos L, Vojnic M, Plodkowski AJ, Sabari J, Ng K, Montecalvo J, Chang J, Tai H, Lockwood WW, Martinez V, Riely GJ, Rudin CM, Kris MG, Arcila ME, Matheny C, Benayed R, Rekhtman N, Ladanyi M, Ganji G.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer Discov. 2018 Apr 2. pii: CD-17-1004. doi: 10.1158/2159-8290.CD-17-1004. [Epub ahead of print] PubMed PMID: 29610121.


Read the full paper here.


For more information of the publication, contact Henrik Edgren

Share this article: